FibroGen Inc. (FGEN)

FGEN (NASDAQ:Biotechnology) EQUITY
$58.15
neg -0.70
-1.20%
Today's Range: 58.05 - 58.50 | FGEN Avg Daily Volume: 433,300
Last Update: 06/18/18 - 9:42 AM EDT
Volume: 4,568
YTD Performance: 24.16%
Open: $58.50
Previous Close: $58.85
52 Week Range: $28.50 - $63.00
Oustanding Shares: 83,522,000
Market Cap: 4,936,150,391
6-Month Chart
TheStreet Ratings Grade for FGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 5 4 4
Moderate Buy 0 0 0 0
Hold 0 0 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.00 1.00 1.40 1.40
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -33.77
Price Earnings Comparisons:
FGEN Sector Avg. S&P 500
-33.77 0.00 20.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.94% 100.51% 213.20%
GROWTH 12 Mo 3 Yr CAGR
Revenue -30.02 -0.10 -0.03
Net Income 76.53 1.10 0.00
EPS 76.53 -0.50 0.00
Earnings for FGEN:
EBITDA -0.12B
Revenue 0.13B
Average Earnings Estimates
Qtr (06/18) Qtr (09/18) FY (12/18) FY (12/19)
Average Estimate $-0.58 $-0.42 $-1.58 $-0.53
Number of Analysts 3 3 3 3
High Estimate $-0.50 $-0.10 $-1.00 $1.08
Low Estimate $-0.68 $-0.58 $-2.32 $-2.25
Prior Year $-0.48 $-0.50 $-1.73 $-1.58
Growth Rate (Year over Year) -20.83% 16.67% 8.67% 66.67%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals (GLMD) is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up some 175% in trading today after the company disclosed some encouraging mid-stage trial results. Other NASH plays like Conatus Pharmaceuticals (CNAT) and Fibrogen (FGEN) are rallying hard as well.

FGEN Update Real Money Pro($)

As most are aware I don't often discuss speculative positions that I am long. However I did mention (FGEN) in The Comments Section (I asked Bre…

Programming Note Real Money Pro($)

I will not be writing tomorrow but you will be in the very capable hands of "Meet" Bret Jensen on Wednesday. "Biotech Wednesday?" It's a hot group! Memo to Bret  --  what are your thoughts on FibroGen (FGEN) , ZIOPHARM Oncology (ZIOP) and Intrexon  (XON) ? Thanks Brother Bret!
The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.
Apple and its suppliers are dragging the market down.
Why I like this China-based wealth management firm.
But the indices are in a trading range and it really boils down to finding the right vehicles to ride.

Mid Afternoon Musings Real Money Pro($)

After much volatility we see little volatility today.   The market bent a bit but didn't break in today's trading session.  …
Stop losses do not work in this part of the market.

Back to Basics in Biotech Real Money Pro($)

Stop losses do not work in this part of the market.

Columnist Conversations

SPX-Cash The first short term support @ 2764.41 and holding remains short term bullish. I would still look to...
I caught up with Tyson Foods (TSN) CEO Tom Hayes for an interview on TheStreet that hit on Sunday. Hayes is b...
Gold prices have taken a dive in the wake of the Fed meeting. Interesting move considering how concerned Fed c...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.